Nature：利用溶瘤病毒治疗癌症

sunsong7

Nature vol.477 (7362), (1 Sep 2011) $ `  z4 d, o9 ]
溶瘤病毒（不管是自然的还是人工设计的）喜欢感染和溶解肿瘤细胞。David Kirn及其同事报告了一个第一阶段的临床试验，通过该试验，他们演示了在只有一次注射之后，系统便能够将人工设计的溶瘤病毒JX-594选择性输送到肿瘤组织。肿瘤活体检查结果表明，这种病毒能在癌症中复制，但不能在相邻正常组织中复制。JX-594是设计用来在能够容留表皮生长因子受体/Ras通道的激发的一系列癌症细胞中来复制的。虽然该临床试验并不是设计用来演示临床效果，但其结果却表明，JX-594在一些患者身上也许能引起临床反应。) z, O6 c: Y3 Q& h4 K

9 e+ ]% v1 w$ P( Y3 p$ w) W+ \" ^/ c- yIntravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans
% C+ g* _" z( X" I: x+ u# ?0 y0 wCaroline J. Breitbach,1 James Burke,2, 10 Derek Jonker,3, 4 Joe Stephenson,5 Andrew R. Haas,6 Laura Q. M. Chow,3, 4 Jorge Nieva,2 Tae-Ho Hwang,7 Anne Moon,1 Richard Patt,8 Adina Pelusio,1 Fabrice Le Boeuf,3 Joe Burns,3, 4 Laura Evgin,3, 4 Naomi De Silva,3, 4 Sara Cvancic,3, 4 Terri Robertson,1 Ji-Eun Je,7 Yeon-Sook Lee,7 Kelley Parato,3 Jean-Simon Diallo,3 Aaron Fenster,9 Manijeh Daneshmand,3, 4 John C. Bell3, 4, 11 & David H. Kirn1, 11 - a+ U7 F8 i' a: ^" r
Affiliations Contributions Corresponding author Journal name: Nature  Volume: 477,
! ~6 m+ x9 p* C! e0 A) g( m: IPages: 99–102 Date published: (01 September 2011) doi:10.1038/nature10358 + N6 I) g  Q6 s3 V! J+ h
Received 25 February 2011 Accepted 05 July 2011 Published online 31 August 2011
" U  h) H; q5 m- H9 d# T* e
4 }: N' a! c( V; y! ` The efficacy and safety of biological molecules in cancer therapy, such as peptides and small interfering RNAs (siRNAs), could be markedly increased if high concentrations could be achieved and amplified selectively in tumour tissues versus normal tissues after intravenous administration. This has not been achievable so far in humans. We hypothesized that a poxvirus, which evolved for blood-borne systemic spread in mammals, could be engineered for cancer-selective replication and used as a vehicle for the intravenous delivery and expression of transgenes in tumours. JX-594 is an oncolytic poxvirus engineered for replication, transgene expression and amplification in cancer cells harbouring activation of the epidermal growth factor receptor (EGFR)/Ras pathway, followed by cell lysis and anticancer immunity1. Here we show in a clinical trial that JX-594 selectively infects, replicates and expresses transgene products in cancer tissue after intravenous infusion, in a dose-related fashion. Normal tissues were not affected clinically. This platform technology opens up the possibility of multifunctional products that selectively express high concentrations of several complementary therapeutic and imaging molecules in metastatic solid tumours in humans.4 S0 _! q/ ]1 z. C2 o6 S

& e& m+ u9 f3 |) H
& M2 z8 s& R: n1 i& T/ L4 j7 W% T; L0 o* ?/ [2 w

! o9 O( r. y0 e, O& m4 m  {! w+ K( b3 u$ Y# ]6 N  {; d
http://www.nature.com/nature/jou ... ll/nature10358.html

sunsong7

溶瘤病毒参考文献
0 U# }" q" E1 }& Z# j, v3 ~+ z. k* W

咔啦

这么好

yuyuzhiming

病毒本身是否存在变异可能?如果癌症治好了.但是感染了病毒怎么办?
' S: Y+ p+ o1 ^  |0 f不过还是非常欣赏科学家敢想敢做.$ j. K2 a* D2 h2 C- U* d/ D4 Q
拿了国家的钱,是对纳税人负责人.多些这样近乎疯狂的想法,发现科学未知的领域.也许这才是作为科研工作者应该做的事情.
' A% Q: C% V% K5 H3 h